While the WHO 2022 classification maintains single- vs. multilineage dysplasia as an optional criterion in MDS with low blast count, this criterion has been abandoned in MDS with SF3B1 mutation as Malcovati [14] reported this distinction lacked prognostic impact. Here, SF3B1 is linked to myelodysplastic syndrome.